US Senators Urge PTO’s Vidal To Tackle Pharma Patent Thickets
Thickets Stifle Competition For Generic And Biosimilar Drugs
A bipartisan group of senators has written to the US Patent and Trademark Office, urging it to tackle the impact of patent thickets on the generic and biosimilar drug industries.
You may also be interested in...
The FDA and FTC have been working on improving information exchange about activities which could undermine biosimilar competition, as well as addressing misinformation about factors such as interchangeability.
The Preserving Access to Affordable Generics and Biosimilars Act and the Stop STALLING Act are both a step closer to becoming law after passing voice votes in the Senate Judiciary Committee.
A balanced policy environment that can support biosimilar competition is needed to allow the drugs to flourish in the US, says Amgen’s executive director of marketing and global biosimilars commercial lead Chad Pettit.